Why uniQure (QURE) Is Up 72.9% After FDA Backs AMT-130 Data For Accelerated Approval Prospects

Simply Wall St.06-19 10:38

UniQure recently received positive FDA feedback allowing three-year data from its Phase I/II AMT-130 Huntington’s disease study to form the primary basis of a Biologics License Application for ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2644302080?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-06-19 10:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2644302080","market":"us","top_or_hot":-1,"title":"Why uniQure (QURE) Is Up 72.9% After FDA Backs AMT-130 Data For Accelerated Approval Prospects","media":"Simply Wall St.","content":"<div>\n<p>UniQure recently received positive FDA feedback allowing three-year data from its Phase I/II AMT-130 Huntington’s disease study to form the primary basis of a Biologics License Application for ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/why-uniqure-qure-is-up-729-after-fda-backs-amt-130-data-for\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why uniQure (QURE) Is Up 72.9% After FDA Backs AMT-130 Data For Accelerated Approval Prospects</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy uniQure (QURE) Is Up 72.9% After FDA Backs AMT-130 Data For Accelerated Approval Prospects\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-19 10:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/why-uniqure-qure-is-up-729-after-fda-backs-amt-130-data-for><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>UniQure recently received positive FDA feedback allowing three-year data from its Phase I/II AMT-130 Huntington’s disease study to form the primary basis of a Biologics License Application for ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/why-uniqure-qure-is-up-729-after-fda-backs-amt-130-data-for\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0109394709.USD","symbol_name":"富兰克林生物科技新领域基金A (acc)","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/why-uniqure-qure-is-up-729-after-fda-backs-amt-130-data-for","article_id":"2644302080","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/why-uniqure-qure-is-up-729-after-fda-backs-amt-130-data-for","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2644302080","pubTimestamp":1781836734,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"UniQure recently received positive FDA feedback allowing three-year data from its Phase I/II AMT-130 Huntington’s disease study to form the primary basis of a Biologics License Application for potential accelerated approval, while shareholders also approved amendments to its Dutch articles of association, including a higher authorized share capital and an exclusive U.S. federal court forum for certain disputes.\nThis combination of regulatory momentum and corporate governance changes could...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","QURE":"uniQure N.V.","LABU":"三倍做多标普生物-Direxion","BK4139":"生物科技","AMT":"美国电塔","BK4219":"电信塔房地产信托","BK4588":"碎股","BK4084":"特种房地产投资信托","BK4585":"ETF&股票定投概念","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4534":"瑞士信贷持仓","BK4581":"高盛持仓","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4554":"元宇宙及AR概念"},"translate_title":"为什么FDA支持AMT-130数据以加速审批前景后uniQure(QURE)上涨72.9%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMT":1.5,"QURE":1.5,"LABU":1.5},"content_text":"UniQure recently received positive FDA feedback allowing three-year data from its Phase I/II AMT-130 Huntington’s disease study to form the primary basis of a Biologics License Application for potential accelerated approval, while shareholders also approved amendments to its Dutch articles of association, including a higher authorized share capital and an exclusive U.S. federal court forum for certain disputes. This combination of regulatory momentum and corporate governance changes could reshape how investors view uniQure’s ability to advance AMT-130 and potentially support future funding flexibility. Next, we will examine how the FDA’s willingness to consider three-year AMT-130 data reshapes uniQure’s investment narrative and risk profile. The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 14 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.AdvertisementWhat Is uniQure's Investment Narrative?To own uniQure today, you have to believe that AMT-130 can move from an expensive, loss-making R&D project into a viable commercial product, and that the company can fund that journey without eroding too much shareholder value. The FDA’s willingness to let three-year Phase I/II data anchor an accelerated approval filing, coupled with an explicit Q3 2026 BLA timeline, sharply elevates regulatory outcomes as the key near term catalyst and helps explain the very large recent share price move. At the same time, the AGM-approved increase in authorized share capital underlines that equity dilution remains a live tool to bridge ongoing annual losses of around US$200,000,000. The core risk now is that heightened expectations meet the reality of regulatory review, confirmatory study requirements and continued cash burn. Yet one financing decision in particular could matter more than the headline trial news. uniQure's shares are on the way up, but could they be overextended? Uncover how much higher they are than fair value.Exploring Other PerspectivesQURE 1-Year Stock Price Chart Five Simply Wall St Community fair value estimates for uniQure span roughly US$2 to just over US$100 per share, highlighting how far apart individual views can be. Set against that spread, the new FDA openness to a three year AMT-130 data package, and the prospect of further capital raising, gives you very different scenarios to weigh for future execution and dilution. You may want to compare several of these viewpoints before deciding how you see the trade off.Explore 5 other fair value estimates on uniQure - why the stock might be worth over 2x more than the current price!Reach Your Own ConclusionDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your uniQure research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.Our free uniQure research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate uniQure's overall financial health at a glance.Ready For A Different Approach?Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.Explore 30 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if uniQure might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2644302080","isCrawlerRequest":true}